Human intrahepatic duct cancer cell line and application thereof

Abstract

The invention relates to a human intrahepatic duct cancer cell line and an application thereof. The human intrahepatic duct cancer cell line LICCF is established according to the invention, is clear and definite in algebra, does not have cross contamination, shows unique sensitivity to an inhibitor of a PI3K / mTOR passage and an inhibitor of an MEK1 / 2 passage, has high drug resistance to 5-FU, cis-platinum and FGFR inhibitors, and can be used for establishing in vivo and in vitro tumor drug experiment and drug resistance models, so that an experimental basis is provided for revealing a human intrahepatic duct cancer drug resistance mechanism, reversing the appearance of drug resistance, developing new anticancer drugs and screening human intrahepatic duct cancer related biological markers.

Description

technical field [0001] The present invention relates to a cell line, in particular to a human intrahepatic cholangiocarcinoma cell line and its use. Background technique [0002] Intrahepatic cholangiocarcinoma (ICC), originating from the epithelium lining the secondary intrahepatic bile ducts to interlobular bile ducts, is the second most common malignant tumor of the liver. The incidence of intrahepatic cholangiocarcinoma is increasing globally, surpassing that of hepatocellular carcinoma in some countries. Surgery is the only possible radical cure for ICC, but early diagnosis of ICC is difficult. Only 10% of patients can undergo radical resection, and most patients have reached an advanced stage when they are diagnosed and lose the opportunity for surgery. Even with surgical resection, the recurrence and metastasis rate is still as high as 80% 5 years after surgery. Unfortunately, there is no recognized effective chemotherapy regimen for intrahepatic cholangiocarcinoma,...

AI Technical Summary

Problems solved by technology

Unfortunately, there is no recognized effective chemotherapy regimen for intrahepatic cholangiocarcinoma, and no targeted therapy is available (on the contrary, other gastrointestinal tumors already have effective targeted drugs, such as sorafenib for hepatocellular carcinoma, Herceptin for gastric cancer, Erbitux for colorectal cancer)

Images